Unlock instant, AI-driven research and patent intelligence for your innovation.

Radiative immune guiding operating medicine of colorectal disease and preparation method thereof

A technology for radioimmunization and colorectal cancer, applied in the directions of in vivo radioactive preparations, drug combinations, pharmaceutical formulations, etc., can solve the problems that affect the development and popularization of RIGS, unfavorable patient surgery, etc., and achieve the effect of overcoming the limitations of radiopharmaceuticals

Inactive Publication Date: 2007-05-02
BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is a great inconvenience in clinical use
It includes the reservation of radionuclides. If you want to import it, you need to wait 2-4 weeks, which is not conducive to timely operation of patients. At the same time, the labeling of radiopharmaceuticals is limited by time, marking place and radiopharmaceutical operators, which greatly affects the RIGS. Develop and promote applications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Radiative immune guiding operating medicine of colorectal disease and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Radioactive labeling: take 1.0mg (5.0mg / ml) of CL58 antibody, add 0.1ml pH7.4 phosphate buffer solution (PB), shake well, add 185MBq Na 125 I solution, then add 12-16 μg of NBS, shake gently, after reacting for an appropriate time, add 20 mg of HSA to terminate the reaction. The labeling rate was measured and purified with a PD10 column.

[0017] Freeze-drying of the labeled antibody: take the labeled and purified antibody, the specific activity of the labeled antibody is 3mCi / mg, the antibody concentration is 0.6mCi / ml, and the protective agent human serum albumin (HSA) is added, and the HSA content is 4mg / ml , and the right amount of mannitol. Dispense into clean vials, 0.5ml per vial, using Dura-Dry TM Freeze-drying in a freeze dryer, and freeze-drying was completed after 24 hours. Then the solubility, antibody activity and aggregation of the lyophilized labeled antibody were determined, as well as the deiodination rate and activity changes of the labeled antibody...

Embodiment 2

[0020] (1) Radioactive labeling: Add phosphate buffer solution to the CL58 antibody to adjust the pH to 7.2, shake well, add 111MBqNa 125 I solution, then add 14 μg N-bromosuccinimide, shake well, after sufficient reaction, add human serum albumin to terminate the reaction, and use PD10 column to purify to obtain the antibody after labeling and purification;

[0021] (2) Freeze-drying of labeled antibody: Take the labeled and purified antibody, add human serum albumin, and freeze-dry.

experiment example 1

[0023] Study on the distribution of lyophilized labeled antibody in animals: the lyophilized sample was dissolved in 0.5ml distilled water, diluted with sterile pH7.2 phosphate buffer solution, and then injected into the tail vein of nude mice bearing CL-187 human colon cancer Lyophilized labeled antibody 125 I-CL58, the injection volume is 0.1ml, the radioactivity is 370KBq, and the antibody content is 3.3μg. At the same time, the nude mice were given 1% KI water to seal the thyroid gland 3 days before the administration. 1d, 3d, 5d, and 7d after injection, blood was collected from the eyeball (5 animals in each group), the cervical vertebrae were twisted until death, and the heart, liver, spleen, kidney, lung, stomach, intestine, muscle, bone, and tumor were harvested , weighed, and determined radioactive counts, calculated ID% / g and T / NT ratio. See Table 1 for specific in vivo distribution results.

[0024] From Table 1, we can see that 24 hours after the injection o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A medicine for the radioimmunoguide operation of colon cancer and rectum cancer is prepared from antibody CL58 through making and freeze drying. It features its clinic application at any time.

Description

technical field [0001] The invention relates to a preparation method of a drug for radioimmunoguided surgery, in particular, the invention relates to a method for preparing a drug for radioimmunoguided surgery of colorectal cancer. Background technique [0002] 50% of colorectal cancer patients undergoing radical surgery will eventually relapse, mainly due to difficult-to-find micrometastases. Radioimmunoguided surgery (RIGS, RadioImmunoGuided Surgery) provides a qualitative standard for solving the judgment of micrometastases on the operating table, and provides a reliable means for complete surgical resection of micrometastases. [0003] RIGS is based on radioimmunoimaging (RII, RadioImmunImaging) positioning diagnosis, using hand-held detectors to detect tumors and their metastatic lymph nodes during surgery. Currently, in the application of RIGS for colorectal cancer, monoclonal antibodies such as B72.3 and CC49 prepared by hybridoma technology are mostly used. The rad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K51/00A61P35/00
Inventor 杨志王雪娟林保和张梅颖
Owner BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL